WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that effective February 14, 2025, Paul L. Berns, Neumora’s co-founder and executive chair of the Board of Directors, will transition to chief executive officer and chairman of the Board, and Henry Gosebruch will be leaving the Company. Additionally, Joshua Pinto, Ph.D., will serve as president, Bill Aurora, Pharm.D., will serve as chief operating and development officer, and Michael Milligan will serve as chief financial officer.
Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. To achieve that goal, the Company has built an industry leading pipeline of seven programs, each pursuing therapeutically relevant targets with novel mechanisms of action and best-in-class pharmacology. Neumora believes that each of its programs has the potential to reshape the treatment of its target indication. Across the pipeline, Neumora expects clinical data readouts from all three of its clinical-stage programs in 2025. The pipeline is complimented by a world class team of neuroscience drug developers and company builders and is supported by a strong financial foundation.
“Neumora is poised to reach its potential, working to maximize shareholder value, and most importantly, to make a difference for the millions of people living with brain diseases,” said Paul L. Berns. “We have seven novel neuroscience programs in the pipeline and four clinical data readouts on the horizon, including data from the ongoing Phase 3 program with navacaprant in depression. This provides significant opportunities to improve the treatment of brain diseases and address unmet needs by bringing novel medicines to people who need them most.”
“On behalf of the Board, I would like to thank Henry for his contributions to Neumora and important capabilities created at the Company. We wish him all the best in the future,” Mr. Berns continued.
“I am honored to serve as president of Neumora,” said Dr. Joshua Pinto. “Neumora is in a strong position, advancing studies in some of the most prevalent brain diseases with multiple near-term clinical inflection points. We have an industry leading pipeline and the opportunity to reshape how brain diseases are thought about and treated. I look forward to working with our team in this expanded role as we seek to deliver on that mission.”
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
